HEALTH CATALYST, INC. (HCAT): Price and Financial Metrics


Today's Latest Price: $35.06 USD

1.35 (-3.71%)

Updated Jul 16 11:20am

Add HCAT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 67 in Medical - Services

See all "A" rated Strong Buy stocks

HCAT Stock Summary

  • With a one year PEG ratio of 0.24, Health Catalyst Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.81% of US stocks.
  • Health Catalyst Inc's stock had its IPO on July 25, 2019, making it an older stock than just 0.09% of US equities in our set.
  • HCAT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.45% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Health Catalyst Inc, a group of peers worth examining would be AERI, ARLO, DMRC, ORGS, and PSTG.
  • HCAT's SEC filings can be seen here. And to visit Health Catalyst Inc's official web site, go to
HCAT Daily Price Range
HCAT 52-Week Price Range

HCAT Stock Price Chart Technical Analysis Charts

HCAT Price/Volume Stats

Current price $35.06 52-week high $49.85
Prev. close $36.41 52-week low $17.48
Day low $34.85 Volume 212,797
Day high $36.68 Avg. volume 682,949
50-day MA $29.50 Dividend yield N/A
200-day MA $30.55 Market Cap 1.33B


Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services. The company is headquartered in Salt Lake City, Utah.

HCAT Latest News Stream

Event/TimeNews Detail
Loading, please wait...

HCAT Latest Social Stream

Loading social stream, please wait...

View Full HCAT Social Stream

Latest HCAT News From Around the Web

Below are the latest news stories about Health Catalyst Inc that investors may wish to consider to help them evaluate HCAT as an investment opportunity.

Health Catalyst to acquire healthfinch in cash and stock deal

Health Catalyst (HCAT) has agreed to acquire healthcare IT shop healthfinch for an undisclosed sum in cash and stock.Madison, WI-based healthfinch has developed a workflow integration engine that, it says, delivers insights and analytics into electronic medical record ((EMR)) workflows that automate doctors' ability to close patient care gaps in...

Seeking Alpha | July 9, 2020

Health Catalyst Announces Agreement to Acquire healthfinch, a Healthcare IT Company that has Helped Define the Clinical Workflow Optimization Space with its Award-Winning Software

SALT LAKE CITY, July 09, 2020 -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

Yahoo | July 9, 2020

Health Catalyst Launches New Care Management Solution

SALT LAKE CITY, July 1, 2020 /PRNewswire/ -- Today, Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, announced the launch of its Care Management Suite, a patient-centric data- and…

PR Newswire | July 1, 2020

Hedge Funds Have Never Been This Bullish On Health Catalyst, Inc (HCAT)

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | June 28, 2020

Health Catalyst Participating in the COVID-19 Evidence Accelerator, a Public-Private Partnership to Advance Understanding of COVID-19

Today, Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, announced its participation in the COVID-19 Evidence Accelerator, an expansive public-private partnership that combines the efforts of academic, government, and private sector organizations by applying real-world data to advance the understanding of COVID-19. The COVID-19 Evidence Accelerator was launched by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research (Friends).

Yahoo | June 18, 2020

Read More 'HCAT' Stories Here

HCAT Price Returns

1-mo 18.25%
3-mo 39.43%
6-mo 2.75%
1-year N/A
3-year N/A
5-year N/A
YTD 1.04%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8 seconds.